Conference
A phase I study of adenovirus engineered, interleukin 2 (IL-2) secreting, autologous plasma cell vaccination for the treatment of multiple myeloma.
Authors
Trudel S; Dodgson C; Nanji S; Li ZH; Voralia M; Dube ID; Graham FL; Stewart AK
Volume
94
Pagination
pp. 705A-705A
Publisher
AMER SOC HEMATOLOGY
Publication Date
November 15, 1999
Conference proceedings
BLOOD
Issue
10
ISSN
0006-4971